Ghiggeri GM, Seitz-Polski B, Justino J, et al. - Given that circulating autoantibodies against membrane-bound (phospholipase A2 receptor 1 [PLA2R1] and thrombospondin type-1 domain containing 7A) and intracellular (aldose reductase, SOD2, and α-enolase) podocyte autoantigens can be present in patients with membranous nephropathy, researchers herein investigated their integrated link with clinical results. This analysis involved 285 patients. The outcomes of interest included an eGFR > 60 ml/min per 1.73 m² and remission of proteinuria (<0.3/<3.5 g per d) following 12 months. Positivity for anti-PLA2R1, anti-SOD2, and anti–α-enolase antibodies and higher titers at diagnosis were identified to be related to poor clinical result independently to each other. In Kaplan–Meier analysis, lower eGFR at 12 months was found in patients who were anti-PLA2R1⁺/anti-SOD2⁺ or anti-PLA2R1⁺/anti−α-enolase⁺ vs those who were anti-PLA2R1⁺/anti-SOD2⁻ or anti−α-enolase⁻. Overall, experts concluded that patients with poor clinical results can be identified by integrated serological analysis of autoantibodies targeting membrane-bound and intracellular autoantigens.